Two separate comparisons are worth keeping apart here: what happened within VDPHL01's own placebo-controlled trial (strong evidence), and how VDPHL01's rates compare to a large immediate-release oral minoxidil safety cohort from a different study entirely (weaker, cross-trial evidence).

Put plainly: the hypertrichosis story is genuinely encouraging for VDPHL01. The fluid retention story is not, on the numbers currently available, and repeating the claim that it's "reduced" isn't something this data supports.

Veradermics has published the pharmacokinetic rationale behind VDPHL01, and it explains why fluid retention and hypertrichosis behaved so differently from the cardiac data. Based on a small comparative study (10 male patients) against a 2.5mg immediate-release tablet, the company describes roughly a tenfold gap between the plasma concentration needed to stimulate hair growth (around 1.62 ng/mL) and the concentration associated with cardiac activity (around 20 ng/mL). VDPHL01 is designed to deliver nearly twice the total minoxidil exposure over 12 hours compared to that immediate-release reference dose, and to keep plasma levels above the hair-growth threshold for roughly twice as long, while specifically blunting the peak concentration to stay below the cardiac threshold.

The design is specifically intended to reduce peak-related cardiovascular effects, and the trial data are reassuring on that front (no clinically significant heart rate, blood pressure, or ECG differences versus placebo, and zero cardiac adverse events of special interest). Fluid retention and hypertrichosis are both associated with systemic minoxidil exposure and dose generally, rather than being effects that can simply be assumed to disappear once the peak concentration is flattened. A formulation designed primarily to reduce Cmax can't automatically be expected to reduce these effects too, and on the evidence so far, it hasn't.

There's a genuine confound sitting inside the cross-trial comparison above that's worth pulling apart, because it changes what the fluid-retention finding actually means. VDPHL01 has only been studied at 8.5mg per dose, once or twice daily (8.5mg or 17mg total per day). The Vañó-Galván safety cohort it's being compared against studied "low-dose oral minoxidil," a term the authors themselves define as 5mg per day or less, with individual case examples in the same body of research using doses as low as 1mg daily.

VDPHL01's tested daily exposure is substantially above the ≤5mg/day definition used in that comparison cohort, and at the twice-daily dose (17mg total) is more than three times that upper limit. Fluid retention is a well-established dose-dependent effect of oral minoxidil generally, not something unique to any one formulation. Given that, at least part of VDPHL01's elevated fluid retention rate could plausibly reflect the higher total dose tested, rather than something inherent to the extended-release delivery mechanism itself.

This is a genuinely open, testable question that Veradermics hasn't addressed publicly: whether a lower VDPHL01 dose, delivering total exposure closer to typical low-dose immediate-release regimens, would preserve the flattened peak (and the cardiac benefit that comes with it) while bringing fluid retention back down toward what's seen at those lower doses. No dose-ranging trial testing this has been reported. It's a reasonable hypothesis grounded in known minoxidil pharmacology, not a confirmed result, and it's worth being clear that this is a question for a future company trial to answer, not something anyone should attempt to infer for their own dosing given VDPHL01 isn't an approved or available drug.

Whether a side effect shows up in a table is one question; whether it's bad enough to make people stop taking the drug is a more practically important one, and here the picture is more reassuring. Edema led to discontinuation in roughly 1% of patients across both dosing arms (1.2% once daily, 1.1% twice daily). Hypertrichosis led to zero discontinuations in either arm. Overall discontinuation due to any adverse event was 4.7% (once daily) and 3.4% (twice daily), against 3.5% for placebo.

One serious adverse event occurred in a VDPHL01 patient, an urticaria flare in someone with a pre-existing history of chronic spontaneous urticaria, which investigators didn't consider drug-related. Separately, the trial's only death occurred in the placebo group. Present tolerability is genuinely reasonable. It's a different claim from "the side effects are gone," which isn't what the data shows.

Study '207', the small open-label female Phase 2 trial covered in our earlier article, used a lower dose than the male study, 4.5mg once or twice daily, roughly half the male dose. If dose were the whole story, a lower dose should mean lower rates of dose-dependent side effects. Instead, hypertrichosis occurred in 21.4% of the pooled female group, notably higher than the male data at nearly double the dose, and peripheral edema occurred in 7.1%, broadly similar to the male rates.

This doesn't rule out the dose hypothesis for fluid retention specifically, but it's a real complication worth being honest about: it suggests dose isn't the only variable at play, with sex differences in hypertrichosis susceptibility, along with the much smaller and uncontrolled female sample, also likely contributing. Study '306', the larger placebo-controlled female trial, is what will actually clarify this.

Everything above is six-month, topline, company-reported data, not yet a peer-reviewed publication, and no dose lower than 8.5mg has been tested in a controlled VDPHL01 trial. Study '302' Part B, covering 12 months of treatment, is expected in the second half of 2026, and it's genuinely relevant here: if fluid retention and hypertrichosis are driven by cumulative exposure, as the pharmacokinetic rationale suggests, it's worth knowing whether their rates climb further with longer use or stabilise. A direct head-to-head trial against immediate-release oral minoxidil, at matched doses, doesn't exist and hasn't been announced. Until one does, the true comparison remains an open question rather than a settled one.

Put together, the current data don't establish that extended release reduces fluid retention. The within-trial evidence shows edema is more common with VDPHL01 than with placebo, while the cross-trial comparison suggests a potentially higher rate than conventional low-dose oral minoxidil. But because VDPHL01 has only been tested at substantially higher doses than that comparison cohort, it isn't yet possible to say whether the difference comes from the formulation, the dose, or both.

This article is provided for educational purposes and does not constitute medical advice. VDPHL01 is an investigational drug not approved by any regulator and not available for purchase through any legitimate channel. AmpleLab products are cosmetic formulations, unrelated to VDPHL01, and are not intended to diagnose, treat, cure, or prevent any condition.

AmpleLab.